الفهرس 
COVID-19Only 14 pages are availabe for public view
 |  | from | 149 |  |  |
| | | from | 149 | | |
Abstract
ABSTRACT
Background: Coronavirus disease 2019 (COVID-19) has spread globally and has caused widespread catastrophic damage. Glycated albumin (GA) is the marker that can monitor glycemic control over 2–3 weeks. GA is useful for patients with hemoglobinopathy, renal failure, and pregnancy. Furthermore, GA better reflects postprandial hyperglycemia, nephropathy, retinopathy, arterial stiffening, peripheral vascular calcification, and Alzheimer’s disease than HbA1c.
Objective: To evaluate the association of Glycated albumin biomarker on admission at Intensive Care Unit for mortality and morbidity of severe and critical diabetic COVID-19 patients. Comparing Glycated albumin with APACHE II score on admission and SOFA score for all patients during ICU stay.
Methods: This controlled cross-sectional study (Pilot study) included 60 patients, aged above 18 years old of either sex, admitted for isolation in the Intensive care unit of Ain Shams teaching hospitals and Obour specialized hospital who were PCR positive for COVID-19 during the period of six months from first of April 2022 till first of October 2022.
Results: There was a highly significant relation between glycated albumin and SOFA score among all studied cases. Groups with high GA are directly proportionated with high SOFA score.
Conclusion: GA may be considered as a good sensitive predictor for severity while both SOFA score & APACHE II may be considered as good sensitive predictors for mortality of diabetic patients during ICU stay for severe and critical COVID-19. Moreover, it is an important biomarker for diabetic complications during ICU stay. On the contrary, GA is not a good predictor for morbidity regarding; cardiac, respiratory, and nephrogenic complications